Abstract: A body-weight support system is disclosed, including an improved lift system and method. The system enables not only the support of patients undergoing rehab therapies, but including exercise modes that are both customizable and dynamic in nature, as well as a track system, wherein the system is capable of providing alternative functionality at differing locations. Other features disclosed include a system by which a movable support unit tracks or follows a patient, adjustable and variable supportive forces for users based upon, for example, a percentage of sensed body weight, and a user-interface that may be employed in a mobile, wired or wireless manner and will allow the use of multiple lift systems on a single, looped track system.

Abstract: The invention relates to an apparatus and method for unloading a user's body weight during a physical activity of said user, particularly for gait training of said user, comprising: a plurality of ropes, wherein each rope extends from an associated drive unit, is deflected by a passively displaceable deflection device, e.g. a device that is displaceable by means of the forces in the deflected ropes, and then runs to a first free end of the respective rope, and a node being coupled to said first free ends and being designed to be coupled to said user, wherein the drive units are designed to retract and release the respective rope so as to adjust a current rope force along the respective rope, which current rope forces add up to a current resulting force exerted on said user via said node in order to unload the user upon said physical activity.

Abstract: A three- or four-wheeled mobility walker/rollator including a foldable or collapsible frame assembly including a main or anterior frame assembly and a posterior frame assembly, three or four wheels coupled to the bottom or base of the frame assembly, and at least two crossbar handles coupled to the top of the frame assembly. The crossbar handles are placed one in front of the other with the first posterior crossbar handle being aligned with or slightly behind the middle of the back wheel posterior to the bottom of the walker frame. The crossbars can be of a sufficient width and curvature to provide a continuous support for the forearms when the user is standing, and can provide more frontal plane stability and balance during locomotion compared to the handles of a traditional walker.

Abstract: A compression therapy device may include a wearable article having independently inflatable and deflatable sealed cells. The location of the sealed cells in the article may be tailored to the anatomy of the device user. A method of providing the therapy device may include measuring one or more anatomical areas on the patient where compression is desired, providing the measurement to a device provider, and receiving an article having multiple sealed cells localized at the one or more anatomical areas. A method of manufacturing the therapy device may include receiving a measurement of an anatomical feature of a patient and determining a configuration of seals to be incorporated in a template article. The configuration may result in the sealed cells providing a pressure on the patient's anatomical feature.

Abstract: The present invention relates to a massage device for a vehicle seat including: a linear sequence of inflatable massage cells which may be arranged in succession below a of the vehicle seat, supply lines and venting lines to and from the massage cells, a compressed air pump connected to the supply lines, a valve arrangement for the selective supply of massage cells with compressed air and for the selective venting of massage cells and a control unit controlling the compressed air pump and the valve arrangement, and that the massage cells are designed such that in the inflated state they are wedge-shaped in cross section in a plane parallel to the longitudinal direction of the linear sequence of the massage cells, wherein the wedge shape of all of the massage cells in the linear sequence is oriented in the same direction.

Abstract: A body roller apparatus is provided which enables therapy routines to be performed on various body muscle groups. A frame structure is part of the apparatus and includes a base frame with a generally horizontal user support member having an opening being mounted thereon. The upper end of a roller structure rotatably supports a spherical roller, while its lower end mounts to the base frame so that at least a portion of the spherical roller extends through the opening of the user support member. The user operates the apparatus by positioning themselves upon the user support member and engaging with their body the portion of the spherical roller which extends through the opening. The vertical position of the spherical roller may be adjusted, and the frame structure itself may be collapsible for storage.

Abstract: An adapter assembly for use with a reciprocating treatment device that includes a main body portion having at least a first top male attachment member or a first top female attachment member on a top thereof and at least first and second bottom male attachment members or first and second bottom female attachment members on a bottom thereof.

Abstract: A communication system and method are provided for remotely reproducing a touch pattern or gesture as a vibrotactile output. At a touch screen, a first user device receives a touch pattern by a first user, characterizes the touch pattern as a touch pattern data based upon time and intensity of touch at a plurality of array points of the touch screen, and communicates the touch pattern data to a network. A tactile array patch of micro-vibratory devices is attachable to a garment and worn by a second user. The touch pattern data is wirelessly received from the first user device via the network. Vibration of selected micro-vibratory devices of the tactile array is modulated in timing and intensity in response to the touch pattern data to reproduce the touch pattern.

Abstract: Systems and methods for providing network connectivity and remote monitoring, optimization, and control of pool/spa equipment are provided. “Internet-of-Things” (IoT) functionality is provided for pool and spa equipment in a flexible and cost-effective manner. Network connectivity and remote monitoring/control of pool and spa equipment is provided by various components such as a network communication and local control subsystem installed in pool/spa equipment, and other components. Also disclosed are various control processes (“pool logic”) which can be embodied as software code installed in any of the various embodiments of the present disclosure.

Abstract: The present application describes a drug dispensing device. The device is comprised of an armband, a rigid housing, made of polymeric or composite material, with any geometric shape, which separates in two along the longitudinal axis, incorporating therein a capsule containing a concentrated fluid whose geometric shape allows its storage within said housing. The centre of the top of one of the capsule faces contains a valve which, upon being actuated by at least one flexible tab, by pressing the mouth of the user, is expelled from the inside of the capsule, allowing him to suck the concentrated fluid contained therein. In this way, the device allows the user to correct the reference values quickly and effectively and thus regain the sense of physical safety while practicing sports in extreme situations or while practicing activities in water environments.

Abstract: A connector system for a medical device includes a first connector having an elongate opening, and a second connector including a lock portion, where the first connector is movable relative to the second connector between an initial position where the first connector is not in fluid communication with the second connector and an activated position where the first connector is in fluid communication with the second connector. The system also includes a locking member connected to the first connector. The locking member is transitionable between an unlocked position where the second connector is movable within the elongate opening of the first connector and a locked position where the locking member is configured to engage the lock portion of the second connector to lock the first connector to the second connector in the activated position. The locking member comprises a spring body received by the elongate opening of the first connector.

Abstract: A tamperproof dosage form for oral administration comprising: a caplet comprising first and second ends, a middle region extending between said first and second ends, parallel and oppositely disposed top and bottom faces, and a land interposed between the top and bottom faces and extending along a perimeter of the caplet on a plane parallel to a caplet length axis; and first and second shells, each comprising an open end and a closed dome-shaped end, each fitted over at least a portion of the caplet, the portion comprising at least the first and/or second ends of the caplet and at least part of the middle region. An adhesive substance being arranged between the caplet and the shells at least over a portion of the top and/or bottom faces proximal to the first and second ends of the caplet and a corresponding portion of an inner surface of the closed dome-shaped end of the shells to fixedly join the shells to the caplet.

Abstract: Medication packaging includes a body defining a cavity for disposal of medication. A closure member is disposed with the body. The closure member includes an advancement mechanism and a window that displays indicia of a medication dosage regimen. The closure member is rotatable between a medication accessible configuration and a closed configuration that includes a sealing position and an advance position to incrementally advance the indicia. Systems and methods of use are disclosed.

Abstract: Methods and systems for a drug supply with an associated dosage regimen are described. A plurality of dosage containers are sequentially stored in drug boxes. The dosage containers are associated with a first time of treatment. The drug boxes are associated with a certain recurring time, e.g., morning, afternoon and evening or four boxes associated with four times a day. The entire day is covered by a plurality of drug boxes for treatment. This organizes the drugs such that compliance with complex treatment regimens may be increased. The drugs in each of the dosage containers need not be the same dosage or even the same drugs each time.

Abstract: A pacifier weaning apparatus is provided that includes a shell or shell assembly providing a housing, and a nipple configured to protrude from the housing. The nipple includes a first end adapted to be held by the housing, and an opposing, sucking end adapted for insertion into a user's mouth. The nipple also defines a first chamber and an expandable, second chamber that are both open at the first end and extend in a direction from the first end to the sucking end, and the first chamber being open and the second chamber being closed at the sucking end. And the pacifier weaning apparatus includes an airflow-control component configured to regulate either or both a break pressure at or above which airflow through the first chamber is permitted, or a rate of airflow through the first chamber.

Abstract: An intelligent pacifier estimates its state based on one or more sensors. Based on the estimated state, the pacifier may provide an alert or notification to a child or caretaker regarding the state of the child. The alert or notification may be generated by one or more output transducers and may increase in level depending on the estimated state. An application program communicates with the intelligent pacifier, allowing the caretaker to review and analyze the data collected by the intelligent pacifier, and to configure the intelligent pacifier. Embodiments of the intelligent pacifier may vary in the number and type of sensors, the number and type of estimated states, and the number and type of output transducers. The intelligent pacifier may be constructed as a single device or may consist of a housing that interfaces to a typical pacifier.

Abstract: The present invention provides polymerizable monomers represented by the following general formula (1) that are useful as dental materials. In the general formula (1), Ra is a divalent C6-9 aromatic hydrocarbon group or a divalent C6-9 optionally bridged cyclic hydrocarbon group, R1 and R2 are each a hydrogen atom or a C1-3 alkyl group, R3, R4, R5 and R6 are each a hydrogen atom or a hydrocarbon group, R7 and R8 are each a hydrogen atom or a methyl group, m and n are each independently 0 to 4, and Rb and Rc are each independently a C2-6 linear alkylene or C2-6 linear oxyalkylene group optionally substituted with a C1-3 alkyl group or a (meth)acryloyloxymethylene group in place of a hydrogen atom.

Abstract: An aspect of the present invention relates to a dental cement that includes a first agent including an organic peroxide and a (meth)acrylate; and a second agent including a thiourea derivative, an ascorbate, a vanadium compound, and a (meth)acrylate, where the first agent and the second agent each have a water content that is less than or equal to 1 mass %.

Abstract: Provided herein is a curable silicone composition that has high optical transparency after being cured and that is in a putty form to be hand-mixable. A curable silicone composition contains: a specific organopolysiloxane as a component (1); a specific organohydrogenpolysiloxane as a component (2); a filler as a component (3); and a catalyst as a component (4). The difference between the refractive index of one of the components (1) to (3) that has the highest refractive index and the refractive index of one of the components (1) to (3) that has the lowest refractive index is 0.1000 or less. The complex viscosity of any of constituent compositions of the curable silicon composition before the curable silicone composition is cured is 10 Pa·s to 100000 Pa·s, as measured under predetermined measurement condition.

Abstract: Provided is a beauty care pack including: a support; a shape retaining layer that is laminated on the support so as to be separated from the support by moisture and is formed by electrospinning a polymer material, to maintain moisturizing and hold the shape of the beauty care pack; and a chemical liquid layer that is laminated on the shape retaining layer and is formed by electrospinning a water-soluble polymer material and a functional material, and that is a dry type and melted by moisture, to thus be easily and conveniently stored and packaged, and conveniently used since the dry sheet is attached on the face of a user.

Abstract: The present invention relates to an emulsion-type cosmetic composition for coating keratin fibres, comprising: an aqueous phase, particles comprising: at least one hard wax, preferentially in the form of an aqueous dispersion, having a melting point ranging from 65 to 120° C., the hard wax(es) being present at a total content greater than or equal to 10% by weight relative to the total weight of the composition, preferably at least one aqueous dispersion of particles of at least one film-forming polymer, the film forming polymer(s) preferably being present at a dry matter content greater than or equal to 10% by weight relative to the total weight of the composition, at least one particular emulsifying system capable of dispersing at least the hard wax(es), the total content of hard wax(es) and optionally of additional wax(es) and the total content of emulsifying system being such that the weight ratio of the hard wax(es) plus additional wax(es) to the emulsifying system is less than or equal to 1.

Abstract: Disclosed are methods of treating and protecting teeth against erosion by use of oral compositions comprising polymeric mineral surface active agents, metal ions such as stannous and zinc and combinations thereof. The present methods provide improved resistance of teeth to erosive demineralization or dissolution and prevention of tooth damage by subsequent exposure of teeth to erosive chemicals such as acidic foods and beverages.

Abstract: Provided herein are methods and compositions comprising resorcinol derivatives for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible discontinuities of the skin resulting from skin pigmentation, skin aging, or other disorders are also disclosed.

Abstract: Compositions allowing the stimulation of hyaluronic acid synthesis via an increase in has-2 expression and their use in the treatment of conditions related to a decrease in hyaluronic acid synthesis.

Abstract: Inventive embodiments disclosed herein include formulation embodiments for promoting a reduction in skin pigmentation. The inventive formulation embodiments Hibiscus acids, a Halidrys formulation that includes water; glycerin; Sargassum Muticum Extract and one or more alpha hydroxyl acids in concentrations for reducing melanin concentrations in melanin containing cells upon contact.

Abstract: The present invention has an object to develop a surface-treated powder which shows both of smooth touch during application and good compatibility with skin, and to provide a cosmetic preparation which shows smooth touch during application as well as good compatibility with skin, and is excellent in cosmetic-film uniformity and in cosmetic retentivity by incorporating the treated powder into the cosmetic preparation. The powder for cosmetic preparation resolving the problem is characterized by being surface-treated with theanine.

Abstract: A hair dye composition comprising the following components (A), (B) and (C) and having pH (25° C.) of 7.5 or more and 12 or less: (A): one or more azo dyes selected from the group consisting of the following (A-1), (A-2) and (A-3): (B): a cationic compound (C): 0.1 mass % or more and 8 mass % or less of at least one alkali metal salt of an acid selected from the group consisting of hydrochloric acid, carbonic acid and sulfuric acid.

Abstract: The present invention relates to novel selective 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) inhibitors and the use thereof to prevent age-induced skin structure and function defects.

Abstract: The invention relates to a composition comprising 2% to 5% minoxidil, 0.01% to 15% finasteride and 0.01% to 15% of a prostaglandin analog. In one embodiment, the prostaglandin analog is latanoprost. I a preferred embodiment, the composition comprises 5% minoxidil, 0.1% finasteride and 0.03% latanoprost. The invention also relates to the use of the said composition to reduce hair loss and/or increase regrowth of hair in a human subject.

Abstract: Tooth remineralization compositions are provided for preventing and treating tooth decay and dental erosion in a patient. The composition comprises a remineralizing agent encapsulated in a polymer. In various embodiments, the remineralizing agent may be in a polymeric chitosan microspheres and/or nanospheres and the remineralizing agent comprises calcium and/or phosphate. Methods of preparation and use of the remineralization compositions are also disclosed.

Abstract: The invention relates to multiphasic polymers comprising from 45% to 95% by weight of a first polymer P1 and from 5% to 55% by weight of a second polymer P2, said polymers P1 and P2 being of distinct compositions, said polymer P1 being obtained by polymerization from a mixture of monomers comprising at least one anionic monomer (a) having a polymerizable vinyl group, at least one nonionic hydrophobic monomer (b) having a polymerizable vinyl group, at least one cross-linking monomer (c) and at least one associative monomer (d) having a polymerizable vinyl group and a hydrophobic hydrocarbon chain and said polymer P2 being obtained by polymerization from a mixture of monomers comprising at least one anionic monomer (a?) having a polymerizable vinyl group, at least one nonionic hydrophobic monomer (b?) having a polymerizable vinyl group and at least one cross-linking monomer (c?).

Abstract: A mascara composition includes a vehicle comprising water; a bimodal acrylic polymer including cationic functionality and anionic functionality; an anionic, water-dispersible polyester; and an aliphatic tackifier having a weight average molecular weight less than about 10,000 daltons. Methods of making up the eyelashes are also provided.

Abstract: The present invention provides: a colloid having a self-iontophoresis capacity, comprising elastomer microparticles and a piezoelectric layer encompassing the same; a preparation method therefor; and a cosmetic composition containing the same. According to the present invention, iontophoresis occurs by itself without the help of additional instruments, thereby allowing water-soluble active ingredients in a cosmetic composition to be effectively and transdermally delivered and absorbed.

Abstract: The present invention relates to a liquid cosmetic composition for making up and/or caring for the skin and/or the lips, comprising, in a physiologically acceptable medium, —at least one non volatile oil, —at least hydrophobic silica aerogel particles, —at least one wax with a melting point of greater than or equal to 60° C., —the said composition comprising less than 5% by weight of water relative to the total weight of the composition, and preferably being anhydrous.

Abstract: An anhydrous personal care composition, comprising: (a) 45 to 60 weight % of at least one ester, selected from (i) triglycerides, (ii) diglycerides, (iii) monoglycerides, (iv) monoesters of diols, and (v) diesters of diols; (b) a first wax having a melting point of from 35° C. to 72° C. present in an amount of 5 to 25 weight %; (c) a second wax having a melting point of 73 to 90 C present in an amount of 1 to 10 weight %; and (d) at least one plant oil having a saponification value of from 150 to 275 mg KOH/g present in an amount of 5 to 35 weight.

Abstract: An anhydrous personal care composition, comprising: (a) 45 to 60 weight % of at least one ester, selected from (i) triglycerides, (ii) diglycerides, (iii) monoglycerides, (iv) monoesters of diols, and (v) diesters of diols; (b) a first wax having a melting point of from 35° C. to 72° C. present in an amount of 5 to 25 weight %; (c) a second wax having a melting point of 73 to 90° C. present in an amount of 0.5 to 15 weight %; and (d) at least one plant oil having a saponification value of from 150 to 275 mg KOH/g present in an amount of 5 to 35 weight.

Abstract: The present disclosure provides a method for preparing an anti-wrinkle functional cosmetic substance comprising cutting herbal materials comprising Angelica gigas root, Rehmannia glutinosa root, a paeonia albiflora root, Mentha arvensis, Angelica dahurica root, Scrophularia buergeriana, Rheum undulatum root/stalk/stem, Sanguisorba officinalis root, and Cinnamomum cassia bark into pieces, putting a mixture of the herbal material pieces, talc, a pearl powder, deep ocean water into an extractor, sterilizing the mixture, then fermenting the mixture by mixed lactobacillales strain, and then hot-water extracting the mixture into a solid, freeze-drying the extracted solid into a freeze-dried powder, and dissolving and high-speed mixing the freeze-dried powder, adenosine, and borax in a beeswax, a perilla oil, an Olea europaea (olive) fruit oil, and a Helianthus annuus (sunflower) seed oil heated and Chamaecyparis obtusa water heated.

Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The compositions include a low molecular weight biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, depot gel compositions that can be injected into a desired location and which can provide controlled release of a beneficial agent over a short duration of time. The compositions include a low molecular weight biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.

Abstract: A composition for lubricant formulations is disclosed. The composition may include hypochlorite, dimethicone, and an emulsifier for improvement of lubricity. Methods of making and using the lubricant formulations are also disclosed.

Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.

Abstract: Present invention relates to a low dose pharmaceutical composition, preferably oral composition comprising therapeutically effective amount of [(2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H,5H-10-thia-1,4a-diaza-benzo[a]azulene-3-carbonyl)-amino]-acetic acid (compound A) in the range of 2.5 mg to 60 mg. Present invention also relates to a method of treating inflammatory bowel disease in a mammal by administrating said low dose pharmaceutical composition. Further, present invention relates to a use of the compound A for the preparation of low dose pharmaceutical composition for the treatment of inflammatory bowel disease in a mammal.

Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.

Abstract: Supplement formulations of estrogen blocker, glycogen manager, and muscle recovery solutions and sublingual therapies for increasing absorption rates thereof. The sublingual delivery systems allow the body to absorb up to 94.9% of each dose directly into the bloodstream, completely bypassing the digestion process. Sublingual delivery (under the tongue) results in potencies 4 to 5 times greater than most capsules and powders. An estrogen blocker solution includes purified water, vegetable glycerin, polypropylene glycol, potassium benzoate, citric acid, calcium D glucarate, 7 keto DHEA, IO3, DIM, nettle root extract, Agaricus biporus extract, narigin extract, and quercetin dehydrate. Formulas for glycogen manager, and muscle recovery are also disclosed.

Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.

Abstract: The present invention provides a sugar-depleted fruit or vegetable juice product, wherein said juice product is a fruit or vegetable juice or juice-retaining fruit or vegetable derived matter, wherein said juice product contains at least about 5 g/l gluconic acid and said juice product contains any two or three, of (i) at least about 0.5 g/l Ca2+, (iii) at least about 1 g/l K+, and (iii) at least about 0.1 g/l Mg2+. Also provided are methods of producing the same and the use thereof to assist in maintaining the health and well-being of a subject and in the treatment and prevention of medical ailments, specifically those associated with the over-consumption of glucose and/or sucrose or inappropriate metabolism of glucose, e.g. metabolic syndrome, diabetes mellitus type II, obesity, dyslipidemia, insulin resistance, hypertension and liver steatosis.

Abstract: The invention relates to a pharmaceutical composition comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids and/or not more than 10 mole percent of PEGylated lipids, the liposomes having a selected mean particle diameter in the size range of 40-200 nm and comprising a first corticosteroid in water soluble form, for the site-specific treatment of inflammatory disorders in humans, providing in human patients a fast, strong, and durable anti-inflammatory effect for at least 2 weeks at a dose of at most 5 mg/kg body weight of prednisolone or an equipotent dose corticosteroid other than prednisolone at a treatment frequency of at most once per two weeks.

Abstract: Provided is a molecular imprint polymer that is capable of acquiring stealth properties through a new mechanism. The molecular imprint polymer according to the present invention, which has a plasma protein recognition sites molecularly imprinted by a plasma protein thereon and contains a constituent derived from a biocompatible monomer, is an in vivo stealth nanoparticle to be used in intravascular delivery. As the plasma protein, albumin is preferred. When carrying a drug thereon, the in vivo stealth nanoparticle according to the present invention is usable as a drug for drug delivery system.

Abstract: Polymer microspheres for embolizing blood vessels and optionally delivering therapeutic agents are provided. The microspheres include PLGA 50:50 and/or Ptx, and are generally formed by emulsion means.

Abstract: The present disclosure disclosed a microsphere-producing process involving three integrated unit operations, 1) microspheres formation; 2) microsphere quality control; 3) post formation microsphere treatment. The first unit operation, i.e. unit operation 1) is integrated with four essential functions: forcing the particle forming materials to pass through a porous membrane to form embryonic micropsheres; enforcing the embryonic microspheres to detach the porous membrane; solidifying the embryonic microspheres; collecting and outputting the solidified microspheres. The quality control unit operation consists discrimination and ejection of oversized microspheres. The post treatment unit operation is integrated with two essential functions, smoothing the microsphere surfaces and reducing organic solvents trapped inside of microsphere matrix.